HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.
August 11, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Akebia Therapeutics' stock rating has been reiterated as Neutral by HC Wainwright & Co. with a maintained price target of $2.
The reiteration of a Neutral rating indicates that the analyst does not see any significant changes in the company's performance in the near future. The maintained price target of $2 also suggests that the analyst believes the stock is fairly valued at its current price. This could lead to a neutral or stagnant short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100